LoPinto-Khoury Carla
Department of Neurology, Lewis Katz Temple School of Medicine, Philadelphia, Pennsylvania.
Semin Neurol. 2022 Oct;42(5):583-593. doi: 10.1055/a-1958-0802. Epub 2022 Oct 10.
Most patients with epilepsy will benefit from seizure control with one of an array of chronic antiseizure medications. Knowledge of the potential long-term effects of these medications is critical to prevent adverse consequences on overall health. Antiseizure medications vary in their capacities to affect the brain and peripheral nerves, hormones, bone mineralization, cardiovascular risk, renal health, hepatic, hematological, and dermatological systems. Understanding of pathophysiology and population risk has evolved, although most of the data available are still on older generation antiseizure medications such as phenytoin, carbamazepine, and valproic acid. The enzyme-inducing properties of some antiseizure medications make their effects on cardiovascular risk and bone health detrimental. Few clear guidelines exist for monitoring long-term effects of medication therapy for epilepsy. When selecting an antiseizure medication, consideration should be given to the individual patient's risks of adverse consequences on other organ systems. During monitoring of patients on chronic therapy, screening tools such as metabolic panels and bone density measurements can help stratify risk and guide management.
大多数癫痫患者可通过使用一系列慢性抗癫痫药物中的一种来控制癫痫发作而获益。了解这些药物潜在的长期影响对于预防对整体健康的不良后果至关重要。抗癫痫药物在影响大脑和周围神经、激素、骨矿化、心血管风险、肾脏健康、肝脏、血液学和皮肤系统的能力方面各不相同。尽管现有大多数数据仍基于苯妥英、卡马西平和丙戊酸等老一代抗癫痫药物,但对病理生理学和人群风险的认识已经有所发展。一些抗癫痫药物的酶诱导特性使其对心血管风险和骨骼健康产生不利影响。关于监测癫痫药物治疗长期影响的明确指南很少。选择抗癫痫药物时,应考虑个体患者对其他器官系统产生不良后果的风险。在对接受长期治疗的患者进行监测时,代谢指标和骨密度测量等筛查工具有助于分层风险并指导管理。